Company Profile
    •  PARI Pharma GmbH 
|

Welcome.


We've been pioneering healthcare improvements for over 100 years, and have built a reputation for delivering innovation and quality. Guided by a world-class research lab, we develop products that continually advance the science of respiratory care.

Welcome.


We've been pioneering healthcare improvements for over 100 years, and have built a reputation for delivering innovation and quality. Guided by a world-class research lab, we develop products that continually advance the science of respiratory care.

Welcome.


We've been pioneering healthcare improvements for over 100 years, and have built a reputation for delivering innovation and quality. Guided by a world-class research lab, we develop products that continually advance the science of respiratory care.

Welcome to PARI Pharma!

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.

We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent® Technology (upper respiratory) Advanced Aerosol Delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.

July 01, 2013 |

ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI

ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

more
May 22, 2013 |

Cardeas Pharma Completes $34 Million in Series B Financing

Proceeds Will Continue to Advance Clinical Development of Innovative Therapies to Combat Multi-Drug Resistant Bacterial Infections

more
November 13, 2012 |

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE®

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment

more
August 30, 2012 |

Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc.

Marlborough, Mass., August 30, 2012 – Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has signed a definitive agreement (“Agreement”) to acquire Elevation Pharmaceuticals, Inc. (Elevation), a privately held...

more